APA (7th ed.) Citation

TJ, R., CB, M., AD, F., A, L., M, F., KM, H., . . . LJ, W. (2026). A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib. Thyroid : official journal of the American Thyroid Association, 36(6), 682. https://doi.org/10.1177/10507256261448706

Chicago Style (17th ed.) Citation

TJ, Roberts, Meador CB, Fuld AD, Lasko A, Frigault M, Hangar KM, Reynolds K, Sadow PM, and Wirth LJ. "A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma After Progression on Selpercatinib." Thyroid : Official Journal of the American Thyroid Association 36, no. 6 (2026): 682. https://doi.org/10.1177/10507256261448706.

MLA (9th ed.) Citation

TJ, Roberts, et al. "A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma After Progression on Selpercatinib." Thyroid : Official Journal of the American Thyroid Association, vol. 36, no. 6, 2026, p. 682, https://doi.org/10.1177/10507256261448706.